Evidence map›Paper›PMID 40747998›Full record

ArticlePharmaceutical biology2025

Unveiling the cytotoxicity of Red Sea

Esraa M Abdelhady, Mohammed N A Khalil, Mohamed A Rabeh, Saad A Alshehri, Omar Sabry, Mona M Hashem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Esraa M AbdelhadyPharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.ORCID 0009-0003-8293-7453
Mohammed N A KhalilPharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID 0000-0002-1134-1164
Mohamed A RabehPharmacognosy Department, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Saad A AlshehriPharmacognosy Department, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0001-6266-7116
Omar SabryPharmacognosy Department, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.ORCID 0000-0002-5796-2708
Mona M HashemPharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID 0000-0001-9240-080X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextBreast and liver cancers remain significant global health challenges, necessitating the discovery of novel anticancer agents. Marine cyanobacteria, such as

objectiveThis study aims to identify and characterize bioactive compounds from MATERIALS AND

methods

resultsLC-QTOF-MS/MS analysis identified 25 metabolites, including apocarotenoids, spirovetivane alkaloids, and toxins. Network pharmacology analysis suggested that malyngamide D, isomalyngamide I, mueggelone, 11,12-didehydrospironostoic acid, and 12-hydroxy-2-oxo-11-epi-hinesol were potential bioactive compounds targeting proto-oncogene tyrosine-protein kinase (Src), mitogen-activated protein kinase 3(MAPK3), and MAPK1 kinases. Molecular docking studies further supported these findings, with 11,12-didehydrospironostoic acid exhibiting strong binding affinities to Src and MAPK1 kinases. Among the nine fractions obtained, Fraction 1 showed the most potent anticancer activity against both MCF-7 and HepG2 cell lines, with IC DISCUSSION AND

conclusionThe results of this study highlight the potential of

Indexed as

Antineoplastic AgentsCyanobacteriaBreast NeoplasmsChromatography, LiquidHep G2 CellsHumansIndian OceanLiver NeoplasmsMCF-7 CellsMolecular Docking SimulationNetwork PharmacologyProto-Oncogene MasTandem Mass SpectrometryAntineoplastic AgentsMAS1 protein, humanProto-Oncogene Masand cyanobacteriaLC-QTOF-MS/MSmolecular dockingMoorena producensnetwork pharmacology

Identifiers

PMID40747998
PMCPMC12320260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.